Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bayer Launches Novel Anti-Clotting Drug in China

publication date: Jul 3, 2009

Bayer Healthcare has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval. As Liam Condon, Managing Director of Bayer HealthCare China said at last week’s ChinaBio® Partnering Forum, the fact that Xarelto was approved in China before the US shows Bayer’s commitment to bringing innovative drugs to China simultaneously with other major world markets. Xarelto is an oral medication, taken once daily, that was approved for the relatively narrow indication of preventing deep vein thrombosis in patients who undergo knee or hip replacement surgery. More details...

Stock Symbol: (Xetra: BAYG.DE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here